The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: A children's oncology group study

Pediatric Blood and Cancer

Volumn 55, Issue 3, 2010, Pages 414-420

  Johnston, Donna L ^a   Alonzo, Todd A ^b   Gerbing, Robert B ^c   Lange, Beverly J ^d   Woods, William G ^e  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

AML; Central nervous system; Leukemia; Pediatric

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME 16; CHROMOSOME ABERRATION; CYTOGENETICS; DIPLOIDY; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; FEMALE; HEPATOMEGALY; HUMAN; INCIDENCE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RISK ASSESSMENT; RISK FACTOR; SPLENOMEGALY; ADOLESCENT; ADULT; CENTRAL NERVOUS SYSTEM TUMOR; GENETICS; INFANT; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; SURVIVAL RATE;

ADOLESCENT; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 77955489676     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22511     Document Type: Article

References (32)

1. Bisschop MM, Revesz T, Bierings M, et al. Extramedullary infiltrates at diagnosis have no prognostic significance in children with acute myeloid leukemia. Leukemia 2001;15:46-49.
2. Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005;19:2030-2042.
3. Pui C-H, Dahl GV, Kalwinsky DK, et al. Central nervous system leukemia in children with acute nonlymphoblastic leukemia. Blood 1985;66:1062-1067. (Pubitemid 16250268)
4. Abbott BL, Rubnitz JE, Tong X, et al. Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: A single institution's experience. Leukemia 2003;17:2090-2096.
5. Webb DH, Harrison G, Stevens RF, et al. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 2001;98:1714-1720.
6. Gibson BES, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005;19:2130-2138.
7. Kobayashi R, Tawa A, Hanada R, et al. Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia. Pediatr Blood Cancer 2007;48:393-398. (Pubitemid 46340103)
8. Chang H, Brandwein J, Yi Q, et al. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leuk Res 2004;28:1007-1011.
9. Woods WG, Kobrinsky N, Buckley J, et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: A Childrens Cancer Group pilot study. J Clin Oncol 1993;11:1448-1457.
10. Grier HE, Gelber RD, Camitta BM, et al. Prognostic factors in childhood acute myelogenous leukemia. J Clin Oncol 1987;5:1026-1032.
11. Rubintz JE, Razzouk BI, Lensing S, et al. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer 2007;109:157-163. (Pubitemid 46120203)
12. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrowtransplantation, autologous bone marrowtransplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001;97:56-62.
13. Lange BJ, Dinndorf P, Smith FO, et al. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group study 2941. J Clin Oncol 2004;22:150-156.
14. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a Children's Oncology Group phase 3 trial for untreated pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Blood 2008;111:1044-1053.
15. Ravindranath Y, Steuber CP, Krischer J, et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: A pediatric oncology group study. J Clin Oncol 1991;9:572-580.
16. Johnston DL, Alonzo TA, Gerbing RB, et al. Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol 2005;23:9172-9178.
17. Pui C-H, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukemia. Lancet Oncol 2008;9:257-268.
18. Pui C-H, Raimondi SC, Srivastava DK, et al. Prognostic factors in infants with acutemyeloid leukemia. Leukemia 2000;14:684-687.
19. Pinkel D,Woo S. Prevention and treatment of meningeal leukemia in children. Blood 1994;84:355-366. (Pubitemid 24215931)
20. Martinez-Climent JA, Garcia-Conde J. Chromosomal rearrangements in childhood acute myeloid leukemia and myelodysplatic syndromes. J Pediatr Hematol Oncol 1999;21:91-102.
21. Barnard DR, Alonzo TA, Gerbing RB, et al. Comparison of childhood myelodysplastic syndrome,AMLFABM6 or M7,CCG2891: Report from the Children's Oncology Group. Pediatr Blood Cancer 2007;49:17-22.
22. Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplasic syndrome in children with Down syndrome: Children's Cancer Group studies 2861 and 2891. Blood 1998;91:608-615.
23. Creutzig U, Reinhardt D, Diekamp S, et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005;19:1355-1360.
24. Gamis AS, Alonzo TA, Hilden JM, et al. Outcome of Down syndrome (DS) children with acute myeloid leukemia (AML) or myelodysplasia (MDS) treated with a uniform prospective clinical trial - Initial repot of the COG trial A2971. Blood 2006;108:9a.
25. Gamis AS,Woods WG, Alonzo TA, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia:Areport from the Children's Cancer Group study 2891. J Clin Oncol 2003;21:3415-3422.
26. Chen AR, Alonzo TA, Woods WG, et al. Current controversies: Which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - An American view. Br J Haematol 2002;118:378-384. (Pubitemid 34994638)
27. Creutzig U, Reinhardt D. Current controversies: Which patients with acute myeloid leukaemia should receive a bone marrow transplantation?-A European view. Br J Haematol 2002;118:365-377.
28. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: Clinical characteristics and treatment outcome in a cooperative pediatric oncology group study - POG 8821. Blood 1999;94:3707-3716.
29. Meshinchi S, Arceci RJ. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist 2007;12:341-355. (Pubitemid 46562369)
30. Kalwinsky DK, Raimondi SC, Schell MJ, et al. Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J Clin Oncol 1990;8:75-83.
31. Dusenbery KE, Howells WB, Arthur DC, et al. Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia. J Pediatr Hematol Oncol 2003;25:760-768.
32. Chang M, Raimondi SC, Ravindranath Y, et al. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): Univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821. Leukemia 2000;14:1201-1207.